AT-7687, a novel GIPR peptide antagonist, combined with a GLP-1 agonist, leads to enhanced weight loss and metabolic improvements in cynomolgus monkeys.

Although the combination of AT-7687 and liraglutide did not reach statistical significance compared to liraglutide monotherapy, it did result in a numerically greater BW reduction (16.3% vs. 12.4%).

also in 111,027 other papers